The survival time after treatment with targeted cancer drugs is related to the patient’s sensitivity to the drug, cancer condition, etc. Therefore, the survival time varies from patient to patient. Currently, targeted drug treatment for cancer is a hot research topic because patients have less systemic reaction after taking the drug and patients with genetic targets have better treatment effect. If the patient is in the early stage of cancer, the tumor is relatively limited and has not yet metastasized, and the corresponding target is found in the genetic test, generally these patients have a better prognosis after treatment with targeted drugs, and some of them can even survive for a long time until natural death. Some patients can even survive for a long time until natural death. However, some patients may develop tolerance to targeted drugs during treatment, and the survival time will be shortened at this time, and the degree of shortening is related to the speed of tumor development. Not all patients are suitable for the application of targeted drugs, and genetic testing should be done before using targeted drugs. In addition, the earlier cancer patients are treated, the better the prognosis is.